Published • loading... • Updated
US FDA approves first mRNA flu shot from Moderna
The shot showed 26.6% better effectiveness than a licensed standard-dose flu vaccine in a late-stage trial of more than 40,000 adults.
- On Wednesday, the Food and Drug Administration approved the United States' first mRNA-based flu vaccine for adults 50 and older, Moderna announced, offering what Moderna CEO Stephane Bancel called an "important new option for America's seniors."
- The FDA initially declined to review the vaccine in February, citing inadequate trials despite conflicting internal feedback, but reversed course two weeks later and agreed to evaluate the shot.
- Clinical trials involving over 40,000 adults found the vaccine about 27% more effective than standard shots during the 2024–25 season; an independent Advisory Committee unanimously voted in June that benefits outweigh risks.
- Moderna expects the vaccine available this fall; however, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has not met since March, potentially delaying formal recommendations.
- While an mRNA-based flu and Covid-19 vaccine was approved in Europe earlier this year, HHS Secretary Robert F. Kennedy Jr. canceled about $500 million in mRNA projects, claiming these vaccines fail to protect against infections.
Insights by Ground AI
19 Articles
19 Articles
The Food and Drug Administration (FDA) on Wednesday approved the first mRNA-based flu vaccine in the United States for adults 50 and older, Moderna announced. “Flu remains a significant public health challenge, and mFLUSIVA offers an important new option for older adults in the United States,” Moderna CEO Stephane Bancel said in a statement. “This approval also reflects the continued potential of our mRNA platform to help address important publi…
·Chevy Chase, United States
Read Full Article
Coverage Details
Total News Sources19
Leaning Left4Leaning Right2Center12Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
